International Journal of Breast Cancer / 2015 / Article / Tab 1

Research Article

Perspectives of Cosmesis following Breast Conservation for Multifocal and Multicentric Breast Cancers

Table 1

Summary of demographic, clinicopathologic, and outcome data for study population.

Clinicopathologic characteristicMFMCBC ()Multifocal (MF)Multicentric (MC) value
(%)(%)(%)

Age in years
 Median (range)45.5 (28–67)45.5 (31–67)45.0 (28–52)0.26
 Mean (SD)46.08 (9.6)47.5 (11.2)43.9 (6.2)0.26

Ethnicity
 Chinese 28(70.0)19(67.9) 9(32.1)0.20
 Other Asian 11(27.5) 5(45.5) 6(54.5)
 Caucasian 1(2.5) 0 1(100)

Mode of presentation
 Symptomatic tumours29(72.5)18(62.1)11(37.9)0.67
 Screen detected lesions11(27.5) 5(45.5) 6(54.5)

Pathologic tumour size in mm
 Median (range)20.018.5 (0–72)20.0 (0–55)
 Mean (SD)19.6 (14)20.0 (14.9)20.1 (12.22)0.99
 <20 mm (T1)23(57.5)14(60.9)9(39.1)0.85
 20–<50 mm (T2)14(35.0)8(57.1)6(42.9)
 >50 mm (T3) 2 (5.0)1(50.0)1(50.0)
 Skin and/or chest wall involved (T4) 1 (2.5)01(100)

Stage at diagnosis
 0 5(12.5)4(80.0) 1(20.0)0.06
 I13(32.5)9(69.2) 4(30.8)
 II17(42.5)7(41.2)10(58.8)
 III 5(12.5)4(80.0) 1(20.0)
 IV 0

Histological type
 DCIS 5(12.5) 4(80.0) 1(20.0)0.21
 Invasive ductal30(75.0)19(63.3)11(36.7)
 Invasive lobular 4(10.0) 1(25.0) 3(75.0)
 Other invasive 1 (2.5) 0 1(100)

Grade
 DCIS 5(12.5) 4(80.0)1(20.0)0.02
 1 6(15.0) 3(50.0)3(50.0)
 213(32.5) 4(30.8)9(69.2)
 315(37.5)13(86.7)2(13.3)
 Unknown 1(2.5)1(100)

Hormone-receptor status
 Positive28(70.0)15(53.6)13(46.4)0.51
 Negative10(25.0) 7(70.0) 3(30.0)
 Unknown 2(5.0) 2(100) 0

Neoadjuvant medical therapy
 No11(27.5) 5(45.5) 6(54.5)0.25
 Yes29(72.5)19(65.5)10(34.5)

Surgical procedure
 BCT34(85.0)21(87.513(81.30.46
 Mastectomy by need 5(12.5) 2 (8.3) 3(18.7)
 Mastectomy by choice 1(2.5) 1 (4.2)

Reoperations 4(10.0)
 Axillary dissection 1(2.5) 1
 Missed multicentric 3 (7.5) 3

Recurrence
 Locoregional recurrence1 (2.5)1
 Distant disease/death2 (5.0)11

Median follow-up (months)59
(range)(43–75)

5-year breast cancer-specific survival95.7%100%87.5%Log-rank test: 0.47

5-year disease-free survival92.7%100%80.8%Log-rank test: 0.52

MFMCBC: multifocal, multicentric breast cancer.
BCT: breast conservation treatment; SD: standard deviation.
Dimension of largest lesion.
+Percentage expressed as the number undergoing BCT in the MF or MC group, respectively.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.